CTOR — CITIUS ONCOLOGY, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1851484 ·
Last close
$0.55
Market Cap
$57.91M
52W High
$1.83
52W Low
$0.49
ADV30
136,614
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,493,788 1,001,945 -8,716,817 -8,923,846 112,093,103 16,563,705 71,708,109
Mar 2026 1,667,298 1,338,420 -28,613,595 -26,609,695 100,699,168 2,632,634 65,430,399
Dec 2025 3,944,111 3,154,903 -5,252,276 -5,534,069 109,973,406 7,295,451 51,559,705
Sep 2025 0 — -4,711,512 -4,996,656 100,942,881 3,924,908 56,076,650

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-19,389,240
Investing CF
$-7,000,000
Financing CF
$33,535,991
CapEx
$-7,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.49
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-105,107,566
Inventory
$22,625,945
Receivables
$686,235
ST Investments
—
EBIT TTM
$-45,326,970
Pretax Income TTM
$-45,874,343
Interest Exp TTM
$547,373
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,105,197
EBITDA
—
Free Cash Flow
$-31,167,442
Enterprise Value
$90,680,432
Total Cash
$16,563,705
Total Debt
$10,210,272
Shares Out
105,758,982
Trailing EPS
$-0.48
Book Value
$0.38
ROE
-126.6%
ROA
-29.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 0 -23,522,750 -24,761,369 100,942,881 56,076,650 44,866,231 -5,492,046
Sep 2024 0 -20,572,747 -21,148,747 84,368,878 38,228,539 46,140,339 126,353
Sep 2023 0 -12,121,241 -12,697,241 47,734,895 22,199,235 25,535,660 0
Sep 2022 0 -4,856,599 -5,432,599 42,690,182 6,422,781 36,267,401 0

TTM Snapshot

Revenues TTM
$7,141,570
NetIncome TTM
$-46,064,266
OpCashFlow TTM
—
Assets (Latest)
$112,093,103
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
TNXP Tonix Pharmaceuticals Holding Corp. $57.13M $2.94 —
BOLD Boundless Bio, Inc. $56.90M $2.41 —
LFVN Lifevantage Corp $60.62M $4.78 —
KZIA KAZIA THERAPEUTICS LTD $60.68M $5.31 —
FBIO Fortress Biotech, Inc. $60.70M $1.82 —

News headlines (Yahoo Finance, 1h cache)

Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
2026-11-04 18:45 · Yahoo
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
2026-10-26 17:00 · Yahoo
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum
2026-08-17 12:28 · Yahoo
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
2026-08-12 12:00 · Yahoo
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
2026-08-05 13:17 · Yahoo
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
2026-07-21 13:17 · Yahoo
Citius raises $36.5m for Lymphir commercialisation
2026-05-06 13:04 · Yahoo
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
2026-06-01 11:00 · Yahoo
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
2026-05-06 00:00 · Yahoo
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
2026-04-29 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.